Rona Therapeutics Completes $35 Million Series A+ Financing with Lilly Asia Ventures Participating

July 19, 2024Rona Therapeutics, a leading platform company in the clinical stage of nucleic acid drug development, announced today the completion of$35 Million in Series A+ Financing. This round of financing was led by LongRiver Jiangyuan Investment, with participating investors including Zhaode Investment, BioTrack Capital, Zhongqi Capital, and Lilly Asia Ventures.This is only three months after Rona Therapeutics completed its $33 million Series A funding.On April 9 this year, Rona Therapeutics announced the successful completion of a $33 million Series A financing round.To advance the establishment of its own delivery platform and the development of its drug pipeline. The Series A financing round received support from several top-tier blue-chip biopharmaceutical investment institutions, including Lilly Asia Ventures, CMB International, Platanus, Fengchuan Investment, and Lanting Capital.

LongRiver Jiangyuan Investment, as the lead investor in the A+ round, will join the board of directors of Rona Therapeutics.Highly praised Rona Therapeutics for its innovation capabilities and market prospects in the field of nucleic acid drug research and development. LongRiver Jiangyuan Investment stated: "Rona Therapeutics has successfully brought two best-in-class siRNA metabolism projects into global development, demonstrating differentiated clinical data and platform value. We are deeply impressed by Rona Therapeutics' progress in developing an innovative siRNA pipeline and expanding into CNS and other extrahepatic delivery. We look forward to collaborating with the Rona Therapeutics team to unlock the potential of RNA drugs as transformative therapies to benefit patients worldwide."

Rona Therapeutics CEO and founder, Yi-Bin Shi, stated: "We warmly welcome Jangfar Investments and other new shareholders. Rona Therapeutics is committed to advancing more best-in-class and first-in-class siRNA projects into global clinical trials while promoting additional potential business development opportunities. Leveraging our proprietary RNA platform, we will strive to push boundaries and fully drive the research and development of RNA therapeutics in the areas of metabolism, obesity, renal diseases, and neurodegenerative disorders."

Rona Therapeutics is advancing a pipeline of best-in-class and first-in-class siRNA programs based on a next-generation siRNA platform.Rona Therapeutics' First RN0191 Pipeline as the Best-in-Class PCSK9 siRNA Project, has completed Phase I clinical trials in Australia and China, and is actively advancing the Phase II clinical development for hypercholesterolemia.RN0361As the company's second pipeline project, the treatment for hypertriglyceridemia will enter clinical trials in the second quarter of 2024. Rona Therapeutics is also advancing preclinical experiments for innovative pipelines targeting kidney diseases, obesity, and cardiometabolic disorders during the same period.